Research Projects Page

Since our inception as an outcome committee in 2015, we have consistently and considerably expanded our ability to produce rigorous outcomes research. In 2018, we established a more formal program and leadership, including full time outcomes research staff. The result of these allocated resources has been a productive output across multiple specialty disease states. Below are highlighted outcomes from studies completed in recent years.

Research Project List

Filter
Research categories (field_research_categories)
Filter
Research categories (field_research_categories)
131-133 of 133 results

Retreatment of Genotype 1 Hepatitis C Virus with Sofosbuvir, Simeprevir, and Ribavirin Following Treatment Failure with an NS5A-Containing Direct-Acting Antiviral Regiment

Published September 1, 2017
Prior to the release of sofosbuvir/velpatasvir/voxilaprevir, few options for retreating patients failing HCV direct acting antiviral (DAA) therapy. This study evaluated the effectiveness of sofosbuvir + simeprevir + ribavirin for 24 weeks in retreating patients who previously failed HCV treatment containing an NS5A inhibitor.
View Poster. September 2017

Hepatitis C Treatment in HIV Coinfection: Approaches, Challenges, and Future Opportunities

Published October 17, 2016
While historical treatments combining interferon and ribavirin were less efficacious in HIV/HCV coinfection, modern direct-acting antiviral (DAA) therapies have shown similar clinical efficacy in HIV/HCV coinfection as in HCV monoinfection. In light of these findings, HIV/HCVcoinfected patients may benefit even more from new HCV treatment approaches. This article reviews the many therapeutic options for HIV/HCV coinfected patients with emphasis on avoiding drug-drug interactions.
Download Publication

Real World Assessment of All-Oral, Sofosbuvir-Based, Hepatitis C Therapy at an Academic Medical Center with Integrated Specialty Pharmacy Services

Published September 1, 2016
This study was among the first to evaluate patient outcomes to all-oral, sofosbuvir (SOF)-based, HCV therapies in a real world setting and assess the impact of a clinic-integrated specialty pharmacy on therapy completion. We found higher completion rates in patients filling through VSP (97%) compared to outside pharmacies (93%), and a 100% medication access rate.
View Efficacy and Impact Poster. September 2016
View Efficacy, Discontinuation, and AE Data Poster. May 2016
Full Research Project List